Heineman Thomas Charles
Chief Medical Officer
Heineman Thomas Charles has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Feb 13, 2026.
On the most recent filing, Heineman Thomas Charles is listed as Chief Medical Officer at ONCOLYTICS BIOTECH INC. Inside the rolling window, Heineman Thomas Charles reported 1 open-market purchase totaling $10K in ONCY and no open-market sales.
Companies traded
Other insiders at ONCY
Insider Buying
$10K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Heineman Thomas Charles made?
Heineman Thomas Charles has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Heineman Thomas Charles trade?
Heineman Thomas Charles has filed SEC Form 4 disclosures for 1 company, including ONCY.
When was Heineman Thomas Charles's most recent SEC Form 4 filing?
Heineman Thomas Charles's most recent SEC Form 4 filing on Tracefour is dated Feb 13, 2026.
What is Heineman Thomas Charles's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Heineman Thomas Charles is listed as Chief Medical Officer.
What is Heineman Thomas Charles's total buy and sell value in the current window?
Inside the rolling retention window, Heineman Thomas Charles bought $10K and sold $0 based on SEC Form 4 filings.
What was Heineman Thomas Charles's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 12,132 ONCY shares on 2026-02-12, worth $10K, per SEC Form 4 filings.